Physician profile
George Nune
NPI 1699099358
$13,378.37
in general payments reported to CMS, 2019-2025
59 companies · $4,815 in 2025
The $4,815 reported for 2025 was more than what 87% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2023: $3,172 · 2024: $4,254 · 2025: $4,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $29.88 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,195.83 |
| Education | $29.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,694.52 | 2023-2025 | Zilbrysq, Fintepla, Rystiggo |
| Biogen, INC. | $1,150.71 | 2023-2025 | Vumerity, Tysabri, Qalsody |
| Neuropace, INC. | $1,136.93 | 2019 | |
| Abbvie INC. | $879.73 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $828.15 | 2023-2025 | Nuplazid, Daybue |
| Alexion Pharmaceuticals, INC. | $765.40 | 2023-2025 | Ultomiris, Soliris |
| Pfizer INC. | $714.13 | 2023-2025 | |
| Lilly USA, LLC | $603.46 | 2023-2025 | Kisunla, Emgality, Amyvid |
| Eisai INC. | $555.75 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $475.36 | 2024-2025 | |
| Sk Life Science, INC. | $408.21 | 2023-2025 | Xcopri |
| Emd Serono, INC. | $357.47 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $341.73 | 2023-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $284.36 | 2023-2025 | Vyepti, Rexulti |
| Amneal Pharmaceuticals LLC | $273.09 | 2023-2025 | Crexont, Rytary |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $267.04 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $258.33 | 2023-2025 | Nuedexta, Rexulti |
| Ipsen Biopharmaceuticals, INC | $243.01 | 2023-2025 | Dysport |
| Jazz Pharmaceuticals INC. | $227.39 | 2023-2025 | Epidiolex |
| Grifols USA, LLC | $144.25 | 2025 | Gamunex-C |
| Genzyme Corporation | $136.00 | 2023-2025 | |
| Genentech USA, INC. | $132.27 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Mallinckrodt Hospital Products INC. | $124.37 | 2024-2025 | Acthar |
| Merz Pharmaceuticals, LLC | $107.81 | 2023-2025 | Xeomin, Inbrija |
| Alnylam Pharmaceuticals INC. | $81.86 | 2023-2025 | Amvuttra, Onpattro |
| Amgen INC. | $80.47 | 2023-2025 | Uplizna, Aimovig |
| Neurelis, INC. | $73.58 | 2024-2025 | Valtoco |
| Abbott Laboratories | $60.93 | 2023-2025 | Infinity |
| Kyowa Kirin, INC. | $56.81 | 2023-2024 | Nourianz |
| Immedica Pharma US, INC. | $56.09 | 2023 | |
| Octapharma USA, INC. | $54.24 | 2023-2025 | Panzyga |
| C2n Diagnostics, LLC | $50.64 | 2025 | Precivityad2 |
| Mdd US Operations, LLC | $47.27 | 2023-2025 | Gocovri |
| Ironshore Pharmaceuticals INC. | $45.25 | 2023 | Jornay Pm |
| Azurity Pharmaceuticals, INC. | $44.78 | 2023-2025 | Eprontia |
| Argenx US, INC. | $37.99 | 2023 | Vyvgart |
| Catalyst Pharmaceuticals, INC. | $36.11 | 2023-2024 | Fycompa |
| Ani Pharmaceuticals, INC. | $34.91 | 2025 | Purified Cortrophin Gel |
| Electromed, INC. | $33.44 | 2024 | Smartvest |
| Astrazeneca Pharmaceuticals Lp | $32.99 | 2024-2025 | Wainua |
| Avadel Cns Pharmaceuticals, LLC | $29.97 | 2024 | Lumryz |
| Axsome Therapeutics, INC. | $29.81 | 2025 | Symbravo |
| Cranial Technologies, INC | $29.61 | 2025 | Doc Band |
| Amylyx Pharmaceuticals, INC. | $27.89 | 2023 | Relyvrio |
| Takeda Pharmaceuticals U.S.A., INC. | $27.41 | 2023 | |
| Scilex Pharmaceuticals INC. | $27.07 | 2024 | |
| Tanabe Pharma America, INC. | $25.89 | 2024 | |
| Celgene Corporation | $24.99 | 2023 | Zeposia |
| Tg Therapeutics, INC. | $24.77 | 2025 | |
| Ge Healthcare | $24.13 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.35 | 2023 | Xarelto |
| Horizon Therapeutics Plc | $22.83 | 2023 | Uplizna |
| Sumitomo Pharma America, INC. | $21.98 | 2023 | Aptiom |
| Acorda Therapeutics, INC | $21.14 | 2023 | Inbrija |
| Collegium Pharmaceutical, INC. | $20.78 | 2025 | Jornay Pm |
| Impel Pharmaceuticals INC. | $19.99 | 2023 | Trudhesa |
| Forte Bio-Pharma LLC | $17.16 | 2025 | Tanlor |
| Biomarin Pharmaceutical INC. | $14.80 | 2024 | Brineura |
| Corium, LLC | $7.97 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Nune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.